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ABSTRACT
Patient-reported outcomes (PROs) have become increasingly
prevalent in clinical research and practice. On February 2,
2006, the Food and Drug Administration (FDA) released a
draft guidance document with respect to incorporating PROs
into clinical research endeavors which include FDA involve-
ment. Researchers at the Mayo Clinic worked with FDA
personnel and experts from academia, industry, clinical
research, and clinical practice to facilitate discussion, dis-
semination, and operationalization of the FDA guidance
document. This article introduces a manuscript series that
resulted from this collective effort. Basic terms are deﬁned
and a précis of each article in the manuscript series is given.
The ultimate conclusion to be drawn from this series is that,
while the goals of assessing and analyzing PRO elements of
clinical practice and research are challenging, there now
exists a scientiﬁc foundation that makes achieving these goals
feasible and the results credible. This is vitally important
because after all, at the heart of all healthcare endeavors is
the patient.
Keywords: FDA guidance, patient-reported outcomes, QOL,
quality of life.
Introduction
Patient-reported outcomes (PROs) have become
increasingly important in clinical research and practice
in recent years with the advent of combination thera-
pies and development of novel and targeted agents
with limited but potentially acute side effects. In
response to issues surrounding the measurement
and interpretation of PROs within pharmaceutical
industry-sponsored trials, drug approval applications,
and labeling claims, the Food and Drug Administra-
tion (FDA) released a draft guidance document on
February 2, 2006 (available at http://www.fda.gov/
cder/guidance/5460dft.pdf) [1]. The draft guidance
document outlines how the FDA evaluates PROs when
used as efﬁcacy end points in support of labeling
claims.
The articles in this issue add to the draft guidance
document in that methods are delineated to handle the
various challenges associated with including PROs in
FDA-related clinical trials. For example, in the article
by Sloan et al. [2], methods for handling missing data
and multiple end points are described. The articles of
this issue do not represent a consensus view of all
meeting participants. They do, however, represent an
elaboration of the contents of the draft guidance docu-
ment from the viewpoint of experts from academia,
industry, clinical research, and clinical practice,
informed by reviews from FDA representatives and
2 days of open discussion during a meeting held in
February 2006. This meeting was intended to:
1. Provide a focused process to facilitate discus-
sion of the recent FDA guidance among all
stakeholders;
2. Educate stakeholders on the background, content,
intent, and concerns surrounding the guidance;
3. Provide an opportunity for systematic review and
discussion of the feedback that has been given to
FDA on the guidance and its implications; and
4. Delineate ways to best operationalize the guidance
so that PROs are incorporated into clinical trials
using state-of-the-science knowledge.
Although the manuscripts deal speciﬁcally with
issues related to FDA-related clinical trials, many of
the ﬁndings and recommendations apply to virtually
all research involving PRO assessments. Material
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related to the meeting and manuscript series can be
obtained at http://www.qolpro.org.
PROs: A Primer
Origin of the Term PRO
The term “patient-reported outcome” appeared in lit-
erature after 1999, although terms such as “self-
reported health outcomes” and “patient-generated
outcomes” continue to be used [3,4]. The term PRO
originated after the Harmonization Meeting in 2000
[5]. A working group met to discuss and coordinate
recommendations and to address the need to harmo-
nize outcomes review criteria in the US and European
regulatory agencies. The discussion expanded from
health-related quality of life (HRQOL) to include out-
comes based on data provided by the patient (or
PROs). The working group thereafter became known
as the PRO Harmonization Group. PRO is now used
with increasing frequency in the evaluation of new
therapeutic products, quality-of-life literature, and
reports tied to patient interviews and physician–
patient communication.
PRO Data Capture
Collection of patient-generated information during a
clinical encounter is usually elicited through questions
to establish the history of the illness. Formalized PRO
data gathering in support of product development and
effectiveness is more systematic using standardized
instruments and questions designed to capture explicit
information about intensity or severity of symptoms,
satisfaction with care, or impact on quality of life and
function. In the context of patient care, the clinical
staff must integrate the ﬁndings into a treatment plan,
whereas researchers use the data to characterize ben-
eﬁts of a treatment.
Incorporation of PRO data is intended to result in
improved understanding of the illness experience, and
underscores evidence used for a product claim. The
PRO should, in principle, facilitate the ability to
predict changes in physical, mental, or social function.
The PRO may enhance the understanding of the
disease and treatment when the PRO is correlated
with physiological changes (e.g., sleep patterns, eating
habits, or elimination). Part of the challenge in using
PRO data is the capacity to derive meaning from the
synthesis of the data.
Types of PRO Data
Patient-reported outcome data captured through an
oral history, a discussion, a cognitive interview,
survey items, or electronic equipment can all be
useful. For example, utilization of equipment such as
the talking touch screen might provide a model to
capture PRO data for low-literacy patients [6]. What-
ever the collection method, the types of data are
highly variable, ranging from very speciﬁc (e.g.,
symptom frequency) to more complex evaluations
such as HRQOL assessments. Several examples are
noted as follows:
1. The impact of the disease state on daily living and
social functioning provide insight into the beliefs
of the patient and the social network surrounding
the patient. The relevance of the illness experience
and the impact on the patient’s life should help to
determine whether, and to what extent, the com-
plaints relate to or interfere with daily living or a
patient’s customary social role, self-esteem, and
performance.
2. Symptom information includes descriptors of
severity, intensity, bothersomeness, and the impact
on everyday function. Symptoms such as pain, for
example, serve a protective function by alerting
the individual of impending tissue damage. Other
symptoms may create a level of social discomfort,
pressuring the individual to report inconvenience,
bothersomeness, or dysfunction.
3. Satisfaction provides important feedback for the
clinician, the researcher, and the health-care facil-
ity, and may help to substantiate a claim for
a new product. Satisfaction information can
lead to a deeper understanding of the patient’s
health problem, performance capacity, and
potential disability, not only enhancing the care
delivered but also providing insight into the
desirability of the treatment. Medication satisfac-
tion, a subset of PRO satisfaction, is often dis-
tinguished by its relationship with adherence.
The patient’s beliefs and values may change his
or her willingness to adhere to medication rec-
ommendations. Beliefs not only inﬂuence satis-
faction, but can change perceptions about
symptom relief, medication efﬁcacy, side effects,
convenience, and ideas about the impact on
quality of life [7].
4. The patient’s assessment of HRQOL is considered
an important indicator of treatment effectiveness
and may inﬂuence recovery goals. HRQOL assess-
ment is more complex than some PROs and may
provide information about treatment outcomes in
multiple domains.
5. Finally, PRO information has merit in and of
itself, because PRO data can provide substantial
rationale and scientiﬁc underpinning for the efﬁ-
cacy of other clinical end points. In addition, these
outcomes can be useful to the pharmaceutical
industry in rounding out the picture of the impact
of treatment on health status and function. The
industry may more effectively use the outcome
information to communicate product value to the
clinician and payers [8].
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PRO Users
Patient-reported outcome data provides helpful docu-
mentation for a variety of users. There are times, for
example, when the patient could be the user of these
data. The patient’s primary interest may concern the
likelihood of improvement in daily life [5]. Changes
important for self-care or those that alter the patient’s
personal outcome expectations contribute to critical
judgments about care. Patients may be encouraged to
keep track of changes in their care during follow-up
visits, reinforcing the need to attend to changes in their
health status [9].
The practicing clinician also stands to gain by
improved insight into changes in performance status
or physical symptoms paramount for medical
decision-making (e.g., asthma symptoms reported by
patients with newly exacerbated dyspnea on exer-
tion). PROs may demarcate changes in health status
relevant to treatment effectiveness, discharge, or for
prescription changes. In practice, HRQOL could
easily become the most prominent end point or
outcome measure to show changes from the patient’s
perspective [10]. PROs have already become standard
in chronic disease areas such as arthritis and erectile
dysfunction.
Payer or managed-care organizations may be inter-
ested in the use of PRO information to predict out-
comes. Other interests extend to the associated
reduction in service use or cost of care resulting from
changes in PRO [11]. Regulatory agency decision-
makers also have a stake in PRO information as
primary or secondary end points in a clinical trial,
depending on the condition under study. The informa-
tion could provide insight into the efﬁcacy of new and
existing products or technologies, to enhance or rein-
force a product claim in the approval process.
Patient-reported outcomes in the framework of new
product development include many of the same
requirements as clinical use. These elements include
speciﬁcity of the concept, a conceptual framework,
documentation of data elements and collection
methods, including validated instruments. PROs rep-
resent the perspective of the patient’s experience with
the disease state, and the impact on daily functioning
and general well-being [5]. Capacity to reﬂect this fact
in the reports of product development is essential for
substantiation of a claim.
Project Etiology
The Cancer Outcomes Working Group was an initia-
tive of the National Cancer Institute that produced a
book published in 2005 which summarized key con-
tributions to the literature of cancer patient outcomes
research [12]. During the compilation of that text, it
became apparent that concerns existed among indi-
viduals in the pharmaceutical industry regarding the
viability of PRO assessments in labeling claim-related
studies. Some companies were closing down outcomes
research programs in response to a perceived shift in
FDA opinion away from PRO assessments as end
points in clinical trials. Whether this perception was
real or imagined is open to debate. The point, however,
was that in late 2004, there was real concern among
QOL researchers that the then-pending release of the
FDA guidance document on PROs would result in, at
best, a serious curtailment of their use in clinical
research, and at worst, “the death of QOL research.”
Individuals involved in this project from the Mayo
Clinic approached the FDA Center for Drug Evalua-
tion and Research group regarding this potential
“storm on the horizon.” The premise was to facilitate
the discussion, dissemination, and operationalization
of the pending guidance document by a collective
effort. Writing teams were constructed to cover ﬁve
major themes: Conceptual Issues; PRO Instrument
Selection; PRO Instrument Development Issues;
Validation of PROs; and Analysis, Interpretation,
and Reporting Results Based on PROs. Writing
team members came from a broad spectrum of
stakeholders: academics, clinicians, pharmaceutical
industry researchers, government and regulatory
agency researchers, and patient advocates.
Team leaders were given a charge to produce an
outline for each topic. Each outline was reviewed by all
team members. The editorial process then moved
forward to production of draft versions of the manu-
scripts. The manuscripts were then submitted to the
Mayo Clinic team for central review. Extensive review
processes were followed up to the date of the meeting
in Chantilly, Virginia, February 23–25, 2006. More
than 400 attendees spent 3 days discussing the FDA
guidance document, the draft manuscripts, and other
issues related to incorporating PRO assessments into
clinical research. Detailed directions for revisions for
all the manuscripts were derived from the discussions
that were given to the writing teams. The postmeeting
revision process then continued with input from all
team members via further face-to-face and/or virtual
meetings. The manuscripts were then submitted to
Value in Health for peer-review.
Précis of Each Article
1. Patient-Reported Outcomes: Conceptual Issues
[13]. This article covers such issues as:
a. What is a PRO concept?
b. What is an adequate conceptual framework?
c. What are the consequences of proceeding with
instrument development without a well-
established conceptual framework?
d. Do speciﬁc conceptual issues vary or evolve by
phase of medical product development (i.e.,
Phase I, II, III, or IV trials)?
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2. Patient-Reported Outcome Instrument Selection:
Designing A Measurement Strategy [14] deals
with:
a. What is the recommended process for instru-
ment selection?
b. When is it appropriate to develop, modify, or
adapt a PRO instrument?
c. When is it appropriate to draw individual sub-
scales or items out of assessments to be used
separately as study end points?
d. If you modify a PRO do you have to redo all
validation? What can be used from the original
validation?
e. If you select an existing instrument, what do
you do if the original development and valida-
tion documentation is inadequate?
3. Patient-Reported Outcomes: Instrument Develop-
ment and Selection Issues [15] deals with:
a. What are the basic qualitative research require-
ments during instrument development? For
example, how much preliminary data is
required to justify the aggregation of individual
items into a domain score? How do you know
when you have captured adequately all the req-
uisite subconcepts?
b. When can a single question serve as a PRO end
point? When are multiple items required?
c. What is the best method for constructing a
summary score?
d. How do you deal with respondent burden?
4. What Is Sufﬁcient Evidence for the Reliability and
Validity of Patient-Reported Outcome Measures?
[16] deals with:
a. What evidence of validity must you provide for
a PRO assessment you plan to use in a clinical
trial?
b. What kinds of validation can be performed
concurrently with different types of trials (i.e.,
Phase I, II, III, or IV clinical trials)?
c. How do you validate the equivalence of trans-
lations or electronic versions of established
questionnaires?
d. What is the most appropriate use of item
response theory during instrument develop-
ment and validation?
5. Analysis and Interpretation of Results Based on
PROs [2]:
a. What are the analysis pitfalls with PRO data in
clinical trials and how can they be avoided
(e.g., missing data, multiplicity, etc.)?
b. What are the best (alternative) methods to
assess clinical signiﬁcance of PROs?
6. Interpreting and reporting results based on PROs
[17]:
a. How should null results be interpreted?
b. How do you present PRO data most effectively
in an FDA application? In labeling?
7. Evaluating HRQOL in cancer clinical trials: the
National Cancer Institute of Canada Clinical
Trials Group experience [18] describes how PROs
have been incorporated into cancer clinical trials
in Canada.
8. Patient-reported outcomes to support medical
product labeling claims [19] contains commentary
from the FDA on the guidance document and how
it relates to the other articles in this series; and
ﬁnally,
9. A patient-reported observation [20] presents the
most important perspective of all, that being a
patient.
Conclusions
The goal of this project was to provide a supplement to
the FDA guidance thatwould provide furnish detail and
exposition that is impossible to communicate in the
relatively brief 36-page document.Wehope that readers
will be able to use the recommendations provided in the
accompanying manuscripts to facilitate incorporation
of PRO assessments into the research process. As with
anything worthwhile, assessing and analyzing PRO
elements of clinical practice and research is challenging.
We must do all that we can to make PRO assessment
feasible and credible. If we fail in our task we will have
left out the heart of all health-care research: the patient.
Laurie Burke, Jane Scott, and Donald Patrick were key in
resolving the considerable administrative, political, and logis-
tical challenges this Mayo/FDA joint endeavor entailed.
Numerous members of the FDA who served as panelists
throughout the meeting answered more than 300 individual
questions relating to the guidance document over a period of
3 days. Steven Priori of the International Society for Pharma-
coeconomics and Outcomes Research ﬁrst suggested Value in
Health as a venue for this series and worked tirelessly keeping
us on target. Kristy Vierling and Kara Curry made the orga-
nization of the meeting run as smoothly as is humanly pos-
sible. Martha Hoag, Matthew Jenson, and Jeff Lobland of
the Mayo School of Continuing Medical Education ensured
that the meeting came off without a hitch. Vicki Schmidt is
primarily responsible for all the articles getting submitted and
managing the countless revisions. The writing team leaders
devoted incredible energy and time in responding to our
constant deadline pressures and keeping their individual
teams on target. All of the writing team members contributed
intellectual prowess so that the sum of the contributions was
greater than the individuals. Reviewers donated their time
and expertise to help the articles be as strong as they can be.
All members of the Mayo QOL Team jumped in and more
than made up for the deﬁcits in their leader. Finally, I think
we all owe a debt of thanks to the patients who have con-
tributed their opinions over the years as the science of PROs
has developed. Their patience with our ineptitude as we
learned from our mistakes is unfathomable but totally vital to
the scientiﬁc process.
Source of ﬁnancial support: Funding for the meeting was
provided by the Mayo Foundation in the form of unrestricted
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educational grants; North Central Cancer Treatment Group
(NCCTG) (CA25224-27) and Mayo Comprehensive Cancer
Center grants (CA15083-32).
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